Shares shifted as Cypherpunk Technologies (CYPH) jumped 7.5% to $1.29 on the heels of Nasdaq confirming it has resolved the company's listing deficiency. The stock had dipped below the exchange's $1.00 minimum for 30 consecutive trading days, triggering a formal warning in March. Now that threat is off the table — but the bigger question is whether the underlying business can keep it there.
• The Delisting Cloud Lifts, but It Was the Second Scare in Six Months. Nasdaq notified Cypherpunk on March 4, 2026, that its stock had traded below $1.00 for the required 30-day period. The company had until August 31 to fix it and did so by May 21 — well ahead of the deadline. But this was already the second compliance cycle; Cypherpunk had received a similar letter and regained compliance in December 2025. Repeat brushes with delisting signal chronic price fragility, not a one-off hiccup. Shareholders have already approved a reverse stock split proposal , giving the board a safety valve if the stock dips again.
• A $77 Million Quarterly Loss Exposes the Zcash Bet's Volatility. CYPH posted a net loss of $77.2 million in Q1 2026, driven primarily by unrealized losses on its Zcash treasury as ZEC prices declined sharply.
Cash stood at just $6.7 million, while the reported fair value of ZEC holdings was $73.8 million. That means the company's value proposition lives and dies with one privacy-focused cryptocurrency — it held 314,185 ZEC at an average cost of $335.89, roughly 1.76% of all Zcash in circulation, with a stated goal of reaching 5%. Today's rally was not crypto-driven: Bitcoin and Ethereum were both down slightly.
• The Biotech Legacy Adds a Wild Card. Cypherpunk now operates two distinct engines: a Zcash-centered privacy technology platform and its Leap Therapeutics oncology pipeline.
Sirexatamab, an antibody targeting colorectal cancer, received Fast Track designation from the FDA in May 2026 — a meaningful regulatory milestone that could unlock partnership value. But clinical-stage drug programs burn cash, and operating cash flow was negative $43.9 million over the trailing twelve months.
• Bearish Bets Remain Elevated. Short interest sits at 10 million shares — about 10.3% of the float — and has climbed 40.7% over the past year. That level of skepticism suggests many investors see the compliance fix as cosmetic rather than fundamental.
The delisting risk is gone for now. But with thin cash reserves, a concentrated crypto treasury, and a pre-revenue drug pipeline, CYPH is essentially asking shareholders to make two high-risk bets at once — and the margin for error remains razor-thin.